Search Results 851-860 of 21580 for Inhibition
* Systemic treatment with ruxolitinib or any other JAK inhibitor within 7 days of study entry * Prior use of ruxolitinib to treat GVHD at any time * ...
Prior receipt of a selective FGFR inhibitor. History of calcium and ... Use of any potent cytochrome P450 3A4 inhibitors or inducers within 14 days or ...
Adjustments to dose of calcineurin inhibitor or sirolimus are allowed only to maintain drug levels within therapeutic range. Subject has a Karnofsky ...
Weroha investigates mechanisms of resistance to poly(ADP-ribose) polymerase inhibitors, along with proteomic and transcriptomic profiling, NAD⁺ metabolism, ...
... inhibition of ERK activity in whole blood. In the 108-patient expansion cohort, 32% of patients required dose reduction. The most common treatment-related ...
If you have a paraneoplastic neurologic syndrome, it's generally recommended that you don't use certain cancer medicines called immune checkpoint inhibitors.
Pantoprazole is a proton pump inhibitor (PPI). It works by decreasing the amount of acid produced by the stomach. This medicine is available only with your ...
... inhibitor treatment, 2) FGFR2 fusions who responded on prior FGFR inhibitor treatment and discontinued due to disease progression, 3) with other FGFR ...
... inhibitor and angiotensin II-converting enzyme (ACE) inhibitor has taught us that regulation of the impaired neurohumoral axis is important for improving ...
CYP3A4 Inhibitors, patients chronically receiving drugs that are known potent CYP3A4 inhibitors within 7 days prior to study enrollment, (including but not ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.